Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23485027 | 0.80 | KDM4E (0.33) | KDM4EALDH1A1MAPTPKMGAA | |
| SCHEMBL17811229 | 0.80 | KDM4E (0.33) | KDM4EALDH1A1MAPTPKMKCNH2 | |
| SCHEMBL21569497 | 0.77 | HRH3 (0.33) | DRD3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25139362 | 0.77 | KDM4E (0.31) | KDM4EALDH1A1MAPTPKMKCNH2 | |
| SCHEMBL21018227 | 0.77 | IDH1 (0.33) | KDM4EALDH1A1MAPTPKMKCNH2 | |
| SCHEMBL21017821 | 0.76 | KDM4E (0.30) | KDM4EALDH1A1MAPTPKMCYP2D6 | |
| SCHEMBL19707976 | 0.75 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL17833064 | 0.70 | DRD3 (0.42) | DRD3KDM4EALDH1A1MAPTGAA | |
| SCHEMBL20939178 | 0.69 | PRMT5 (0.40) | — | |
| SCHEMBL19708008 | 0.69 | GABRG2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2019-11-14 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | DRD3 555/4885KDM4E 2085/4885ALDH1A1 448/4885 |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | DRD3 1956/4885KDM4E 1299/4885ALDH1A1 2826/4885 |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | DRD3 105/4885KDM4E 424/4885ALDH1A1 988/4885 |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | HRH3, H1-3, CD274 | DRD3 105/4885KDM4E 424/4885ALDH1A1 988/4885 |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | DRD3 1305/4885KDM4E 1013/4885ALDH1A1 1891/4885 |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | DRD3 555/4885KDM4E 2085/4885ALDH1A1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.